Barbara Newhouse, President and CEO
Lucie Bruijn, Ph.D.
Interview Date: May 9, 2016
S2:E5 ALSA President and CEO Barbara Newhouse and Chief Scientist Dr. Lucie Bruijn spoke live from Washington DC at the National ALS Advocacy Day and Public Policy Conference. They shared the advocacy work on Capitol Hill that the National ALS Association and medical updates that are happening.
Full Transcript will be available in one week from date of show.
Barbara Newhouse has over 35 years of success in leading strategic initiatives resulting in operation growth and market strength. Her specialties are aligning the needs of a varied group of constituents with the overall mission and working with the grassroots chapter and volunteer network while maintaining a strategic business operations focus.
Prior to the ALS Association, her background included executive roles with the American Cancer Society, the Alzheimer Association, the Autism Society of America, and the Arthritis Foundation.
Barb holds a Bachelor degree in Social Work and a Master’s degree in Health Care Administration. She received a Certificate with the Leadership Institute of Aging in 1994 and has attended various continuing education courses with the Kellogg School of Non-Profit. Barb has recently completed a Certificate in Leadership program through the University of Notre Dame on leading transformational organizations.
Throughout her career, she has served on numerous non-profit Boards of directors including chairing both a community mental health center as well as the Governor’s Conference on Alzheimer’s disease for the state of Iowa.
Lucie Bruijn, Ph.D. joined The ALS Association in January 2001 and is currently the Chief Scientist. Prior to that Dr. Bruijn led a team at Bristol Myers Squibb developing in vitro and in vivo model systems for neurodegenerative disease. Her team worked with experts in academia to establish stem cell studies at Bristol Myers Squibb.
Dr. Bruijn received her Bachelor’s degree in Pharmacy at Rhodes University, South Africa. She received a Master’s degree in Neuroscience and a Ph.D. in Biochemistry, at the University of London, United Kingdom. She received her MBA at Imperial College, London, United Kingdom. She joined Dr. Don Cleveland’s laboratory in 1994 where she developed and characterized a mouse model of ALS (mice expressing the familial-linked SOD1 mutation). Using this model her studies focused on disease mechanisms. In addition, in collaboration with Dr. Robert Brown she looked for neurofilament mutations in familial and sporadic ALS patients.
At The ALS Association, Dr. Bruijn leads a global ALS research effort, called Translational Research to AdvanceTherapies for ALS (or TREAT ALS™) with the goal to move treatment options forward. It is her strong belief that only through collaboration among a wide range of disciplines will we be successful in changing the course of ALS and finding a cure.